CHMP approves VPHM’s Cinryze for prophylaxis and acute treatment of HAE, including self administration
In the EU, Shire's Firazyr label was recently amended to include self administration as well, so it's the first and only SubQ self administered agent for acute HAE, an advantage that is hard to compete with. If approved with a similar label by the FDA, I expect it to gain a big share in the acute market. This of course will hurt Dyax's Kalbitor and CSL Behring's Berinert but not VPHM’s Cinryze.
Market Data 
Markets 
AI
